in f У 🛤

Notice of Second Court Hearing

Allkem Limited (ASX and TSX: AKE, "**Allkem**") refers to the proposed scheme of arrangement pursuant to which Arcadium Lithium plc would acquire 100% of the shares in Allkem ("**Scheme**"), in connection with the proposed merger of equals of Allkem and Livent Corporation ("**Livent**").

Subject to:

- the requisite majorities of Allkem shareholders approving the Scheme at the Scheme Meeting to be held virtually and in person at 10:30am (AWST) / 1:30pm (AEDT) on 19 December 2023; and
- Livent stockholders approving the adoption of the Transaction Agreement and the transactions contemplated by it at the Livent stockholders meeting to be held on 19 December 2023 (New York time),

the Court hearing to approve the Scheme (being the "**Second Court Hearing**") is scheduled to take place at 2:15pm (AWST) on 20 December 2023 at the Federal Court of Australia (Western Australian registry).

Attached to this announcement is a notice of that Second Court Hearing, as well as details of how you may file and serve a notice to appear at the Second Court Hearing and any affidavit, and Allkem's address for service.

ENDS

 Allkem Limited
 Investor Relations & Media Enquiries
 Connect

 ABN 31 112 589 910
 M: +61 418 783 701 E: Andrew.Barber@allkem.co
 info@allkem.co

 Level 35, 71 Eagle St
 Phoebe Lee
 www.allkem.co

This release was authorised by the Board of Directors of Allkem Limited.

P: +61 7 3064 3600 E: Phoebe.Lee@allkem.co

IMPORTANT NOTICES

Not for release or distribution in the United States

Brisbane, QLD 4000

This announcement has been prepared for publication in Australia and may not be released to U.S. wire services or distributed in the United States. This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States or any other jurisdiction, and neither this announcement or anything attached to this announcement shall form the basis of any contract or commitment. Any securities described in this announcement have not been, and will not be, registered under the U.S. Securities Act of 1933 and may not be offered or sold in the United States except in transactions registered under the U.S. Securities Act of 1933 or exempt from, or not subject to, the registration of the U.S. Securities laws.



Annexure – Notice of Second Court Hearing

Allkem Limited (ACN 112 589 910) Notice of hearing to approve compromise or arrangement TO: All members of Allkem Limited (ACN 112 589 910) (**Allkem**).

TAKE NOTICE that at 2:15 pm (AWST) on 20 December 2023 the Federal Court of Australia (situated at the Peter Durack Commonwealth Law Courts Building, 1 Victoria Avenue, Perth, Western Australia 6000) will hear an application by Allkem seeking the approval of an arrangement between Allkem and its members, as agreed to by resolution considered by the members of Allkem at a meeting of such members to be held at 10.30 am (AWST) / 1.30 pm (AEDT) on Tuesday, 19 December 2023 at The Studio, Level 2, Crown Towers, Crown Perth Convention Centre, Great Eastern Highway Burswood, Western Australia 6100 and online.

Allkem Limited (ASX: AKE, 'Allkem') refers to the proposed scheme of arrangement pursuant to which Arcadium Lithium plc would acquire 100% of the shares in Allkem ('Scheme'), in connection with the proposed merger of equals between Allkem and Livent Corporation announced to ASX on 10 May 2023.

If you wish to oppose the approval of the arrangement, you must file and serve on Allkem a notice of appearance, in the prescribed form, together with any affidavit on which you wish to rely at the hearing. The notice of appearance and affidavit must be served on Allkem at its address for service at least one day before the date fixed for the hearing of the application.

The address for service on Allkem is:

C/- King & Wood Mallesons Level 30, QV1 Building 250 St Georges Terrace, Perth WA 6000 Attention: James Wang

> John Sanders Chief Legal Officer and Company Secretary Allkem Limited